Literature DB >> 24634386

Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes.

David D Chism1, W Kimryn Rathmell.   

Abstract

Renal cell carcinoma is a heterogeneous disease, and tissue investigations provide clues that may predict treatment response. Oncogenomic analysis of five outliers, who achieved a sustained response with rapalogs, implicates alterations of the TSC1 and mTOR genes and reveals insights into the conserved evolution of tumors. ©2014 AACR.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24634386      PMCID： PMC4077661          DOI： 10.1158/1078-0432.CCR-14-0056

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma.

Authors:  Jeffrey La Rochelle; Tobias Klatte; Aditi Dastane; Nagesh Rao; David Seligson; Jonathan Said; Brian Shuch; Nazy Zomorodian; Fairooz Kabbinavar; Arie Belldegrun; Allan J Pantuck
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

2.  Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma.

Authors:  Robert J Motzer; Carlos H Barrios; Tae Min Kim; Silvia Falcon; Thomas Cosgriff; W Graydon Harker; Vichien Srimuninnimit; Ken Pittman; Roberto Sabbatini; Sun Young Rha; Thomas W Flaig; Ray Page; Sevil Bavbek; J Thaddeus Beck; Poulam Patel; Foon-Yiu Cheung; Sunil Yadav; Edward M Schiff; Xufang Wang; Julie Niolat; Dalila Sellami; Oezlem Anak; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2014-07-21       Impact factor: 44.544

3.  The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.

Authors:  Tamer Abou Youssif; Mona Alam Fahmy; Ismael Herve Koumakpayi; Fernanda Ayala; Saeeda Al Marzooqi; Guangyong Chen; Pheroze Tamboli; Jeremy Squire; Simon Tanguay; Kanishka Sircar
Journal:  Cancer       Date:  2010-09-09       Impact factor: 6.860

4.  Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

Authors:  Antoine Thiery-Vuillemin; Caroline Laheurte; Laura Mansi; Bernard Royer; Xavier Pivot; Christophe Borg; Olivier Adotevi
Journal:  J Immunother       Date:  2014-01       Impact factor: 4.456

5.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

6.  Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy.

Authors:  Martin H Voss; A Ari Hakimi; Can G Pham; A Rose Brannon; Ying-Bei Chen; Luis F Cunha; Oguz Akin; Han Liu; Shugaku Takeda; Sasinya N Scott; Nicholas D Socci; Agnes Viale; Nikolaus Schultz; Chris Sander; Victor E Reuter; Paul Russo; Emily H Cheng; Robert J Motzer; Michael F Berger; James J Hsieh
Journal:  Clin Cancer Res       Date:  2014-03-12       Impact factor: 12.531

7.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

8.  Comprehensive molecular characterization of clear cell renal cell carcinoma.

Authors: 
Journal:  Nature       Date:  2013-06-23       Impact factor: 49.962
  8 in total
  2 in total

1.  Novel mutations and role of the LKB1 gene as a tumor suppressor in renal cell carcinoma.

Authors:  Zübeyde Yalniz; Hulya Tigli; Hatice Tigli; Oner Sanli; Nejat Dalay; Nur Buyru
Journal:  Tumour Biol       Date:  2014-09-02

2.  A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.

Authors:  Erica Nakajima; Paul Leger; Ingrid A Mayer; Michael N Neuss; David D Chism; W Kimryn Rathmell
Journal:  Kidney Cancer       Date:  2017-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.